[1]高 娜,王崇宝.胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1424-1427.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.025]
　GAO Na,WANG Chongbao.Clinical efficacy of thymosin combined with cisplatin and pemetrexed disodium in treatment of advanced non-small cell lung cancer[J].,2022,51(11):1424-1427.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.025]
点击复制

胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌临床疗效研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年11期
页码:
1424-1427
栏目:
药物与临床
出版日期:
2022-11-05

文章信息/Info

Title:
Clinical efficacy of thymosin combined with cisplatin and pemetrexed disodium in treatment of advanced non-small cell lung cancer
作者:
高 娜; 王崇宝
(陕西省中医医院,陕西 西安 710003)
Author(s):
GAO Na; WANG Chongbao
(Shaanxi Provincial Hospital of Traditional Chinese Medicine,Xi'an 710003,China)
关键词:
非小细胞肺癌;  胸腺肽;  培美曲塞二钠;  顺铂;  免疫功能;  肿瘤标志物
Keywords:
Non-small-cell lung cancer;  Thymic peptide;  Pemetrexed disodium;  Cisplatin;  Immunologic function;  Tumor marker
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.11.025
文献标志码:
A
摘要:
目的:探讨胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:选取101例NSCLC患者随机分为对照组(51例)与观察组(50例)。对照组使用培美曲塞二钠与顺铂治疗,观察组使用培美曲塞二钠、顺铂联合胸腺肽治疗,两组均治疗6周。比较两组的免疫指标与肿瘤标志物水平、近期疗效及不良反应发生率。结果:治疗前两组CD3+、CD4+、CD8+、自然杀伤细胞、CD4+/CD8+水平比较,差异无统计学意义(均P>0.05),治疗后第3个月观察组上述指标水平均高于对照组,差异有统计学意义(均P<0.05)。治疗前两组血清胸苷激酶1、癌胚抗原和糖类抗原125的水平比较,差异无统计学意义(均P>0.05),治疗后观察组上述指标水平均低于对照组,差异有统计学意义(均P<0.05)。两组有效率比较,差异无统计学意义(P>0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:胸腺肽联合培美曲塞二钠、顺铂治疗晚期NSCLC可改善患者免疫功能,降低肿瘤标志物水平,应用效果优于培美曲塞二钠与顺铂联合治疗。
Abstract:
Objective:To explore the clinical efficacy of thymosin combined with cisplatin and pemetrexed disodium in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 101 NSCLC patients were selected and randomly divided into the control group(51 cases)and observation group(50 cases).The control group was treated with pemetrexed disodium and cisplatin,and the observation group was treated with thymic peptide on the basis of the control group,then the both groups received treatment for 6 weeks.The immune indicators levels,tumor markers levels,recent efficacy and the incidence of adverse reactions were compared between the two groups.Results:The differences in the levels of CD3+,CD4+,CD8+,natural killer cells and CD4+/CD8+ before treatment were insignificant between the two groups(all P>0.05),and the levels of those indexes in the observation group were higher than those in the control group at 3 months after treatment(all P<0.05).The differences in serum levels of carcoembryonic antigen,thormidine kinase 1 and sugar-class antigen 125 before treatment were insignificant between the two groups(all P>0.05),and the levels of those indexes were lower than those in the control group after treatment(all P<0.05).The differences in effective rate and incidence of adverse reactions were insignificant between the two groups(all P>0.05).Conclusion:Application of thymic peptide combined with pemetrexed disodium and cisplatin in the treatment of advanced NSCLC can improve immune function and reduce the levels of tumor markers,and the application effect was better than the combination treatment of pemetrexed disodium and cisplatin.

参考文献/References:

[1] 胡明明,阳 苑,张同梅,等.7843例原发肺恶性肿瘤流行病学特征分析[J].现代肿瘤医学,2021,29(4):682-685.
[2] 刘枫林,马 伟.肺癌患者临床流行病学及病理学特点分析[J].中国病案,2021,22(5):53-55.
[3] 罗 虎,胡雪婷,王 康,等.晚期肺癌的联合治疗现状及进展[J].临床内科杂志,2020,37(2):86-90.
[4] Igarashi K,Kawaguchi K,Yamamoto N,et al.A novel anionic-phosphate-platinum complex effectively targets a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model[J].Cancer Genomics & Proteomics,2020,17(3):217-223.
[5] 周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:47-48.
[6] Mor V,Laliberte L,Morris JN,et al.The karnofsky performance status scale:An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8] 蔡海红,周 健,刘伟萍,等.老年肺癌晚期病人的个体化安宁疗护[J].实用老年医学,2021,35(9):995-996.
[9] 王翠翠,耿利民.血清癌胚抗原对表皮生长因子受体基因突变非小细胞肺癌分子靶向治疗疗效的预测价值[J].陕西医学杂志,2020,49(7):834-837.
[10] 宣向飞,雷莲莲.培美曲塞二钠联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].中国肿瘤临床与康复,2021,28(4):466-469.
[11] 吴晋周,靳建旭,刘林涛.参芪扶正注射液联合培美曲塞钠+顺铂化疗方案治疗晚期非小细胞肺癌的疗效研究[J].癌症进展,2021,19(13):1341-1344.
[12] 卢瑞琦,郭 昌,孙燕川,等.贝伐珠单抗联合胸腺法新治疗NSCLC合并MPE的疗效及其机制[J].中南医学科学杂志,2020,48(5):484-486.
[13] 艾星浩,蔡 勇,褚 倩,等.放疗联合免疫治疗非小细胞肺癌:前沿学术问题专家交流共识[J].中国肺癌杂志,2020,23(6):132-140.
[14] 张卓红,党升强.胸腺肽对肺癌根治术后患者外周血单个核细胞中Treg比例的影响[J].中国肿瘤临床与康复,2021,28(7):790-793.
[15] 肖 锋,肖茂良,伍世葵,等.新冠肺炎预防2号方联合胸腺法新对晚期非小细胞肺癌化疗后免疫功能的影响[J].辽宁中医杂志,2021,48(8):123-126.
[16] 钱 浓,杨贤科,马红兵.胸腺肽联合GP方案治疗非小细胞肺癌的临床研究[J].药物评价研究,2020,43(5):890-894.
[17] 张晓芳,樊 莉,尤江云,等.外周血免疫细胞表达水平对肺癌患者生存期的影响[J].中国免疫学杂志,2020,36(2):180-185.
[18] 李丽芳,戴献利,侯志华,等.化疗对非小细胞肺癌患者外周血NK细胞受体表达的影响及其临床意义[J].河北医科大学学报,2020,41(2):208-213.
[19] 张明春,宋彩云,朱佳贞.康力欣胶囊联合培美曲塞加顺铂方案治疗晚期非小细胞肺癌的效果及生存情况观察[J].中国药物与临床,2020,20(10):1647-1650.
[20] 范 伟,孙振宇,孟祥宽,等.血清CEA、CYFRA21-1、VEGF、STK1及SF联合检测在非小细胞肺癌患者诊断中的价值分析[J].标记免疫分析与临床,2020,27(3):480-483.
[21] 王 岸,韩 力.多西他赛和顺铂联合胸腺法新治疗非小细胞肺癌的效果及对血清相关因子水平的影响[J].中国肿瘤临床与康复,2021,28(5):569-572.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(11):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(11):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(11):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(11):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(11):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(11):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(11):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

更新日期/Last Update: 2022-11-09